AU4988999A - Compositions and methods of treating abnormal cell proliferation - Google Patents

Compositions and methods of treating abnormal cell proliferation

Info

Publication number
AU4988999A
AU4988999A AU49889/99A AU4988999A AU4988999A AU 4988999 A AU4988999 A AU 4988999A AU 49889/99 A AU49889/99 A AU 49889/99A AU 4988999 A AU4988999 A AU 4988999A AU 4988999 A AU4988999 A AU 4988999A
Authority
AU
Australia
Prior art keywords
methods
abnormal cell
compositions
cell proliferation
vitamin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU49889/99A
Other languages
English (en)
Inventor
Charles C. Achkar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of AU4988999A publication Critical patent/AU4988999A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/671—Vitamin A; Derivatives thereof, e.g. ester of vitamin A acid, ester of retinol, retinol, retinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/007—Preparations for dry skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A61Q5/06—Preparations for styling the hair, e.g. by temporary shaping or colouring
    • A61Q5/065—Preparations for temporary colouring the hair, e.g. direct dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Dermatology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Birds (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
AU49889/99A 1998-07-16 1999-07-13 Compositions and methods of treating abnormal cell proliferation Abandoned AU4988999A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09116632 1998-07-16
US09/116,632 US20010002396A1 (en) 1998-07-16 1998-07-16 Compositions and methods of treating skin conditions
PCT/US1999/015769 WO2000003700A1 (en) 1998-07-16 1999-07-13 Compositions and methods of treating abnormal cell proliferation

Publications (1)

Publication Number Publication Date
AU4988999A true AU4988999A (en) 2000-02-07

Family

ID=22368338

Family Applications (1)

Application Number Title Priority Date Filing Date
AU49889/99A Abandoned AU4988999A (en) 1998-07-16 1999-07-13 Compositions and methods of treating abnormal cell proliferation

Country Status (12)

Country Link
US (2) US20010002396A1 (enExample)
EP (1) EP1104294B8 (enExample)
JP (1) JP2002527356A (enExample)
AT (1) ATE305296T1 (enExample)
AU (1) AU4988999A (enExample)
CA (1) CA2337138A1 (enExample)
DE (1) DE69927507T2 (enExample)
DK (1) DK1104294T3 (enExample)
ES (1) ES2249900T3 (enExample)
MX (1) MXPA01000492A (enExample)
PT (1) PT1104294E (enExample)
WO (1) WO2000003700A1 (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6538037B2 (en) 1991-01-08 2003-03-25 Bone Care International, Inc. Methods for preparation and use of 1α,24(S)-dihydroxyvitamin D2
US5763429A (en) * 1993-09-10 1998-06-09 Bone Care International, Inc. Method of treating prostatic diseases using active vitamin D analogues
US6242434B1 (en) * 1997-08-08 2001-06-05 Bone Care International, Inc. 24-hydroxyvitamin D, analogs and uses thereof
US6503893B2 (en) 1996-12-30 2003-01-07 Bone Care International, Inc. Method of treating hyperproliferative diseases using active vitamin D analogues
US20020128240A1 (en) * 1996-12-30 2002-09-12 Bone Care International, Inc. Treatment of hyperproliferative diseases using active vitamin D analogues
US6566353B2 (en) 1996-12-30 2003-05-20 Bone Care International, Inc. Method of treating malignancy associated hypercalcemia using active vitamin D analogues
US6573256B2 (en) 1996-12-30 2003-06-03 Bone Care International, Inc. Method of inhibiting angiogenesis using active vitamin D analogues
US20030129194A1 (en) * 1997-02-13 2003-07-10 Bone Care International, Inc. Targeted therapeutic delivery of vitamin D compounds
US6087350A (en) * 1997-08-29 2000-07-11 University Of Pittsburgh Of The Commonwealth System Of Higher Education Use of pretreatment chemicals to enhance efficacy of cytotoxic agents
JP2002509888A (ja) * 1998-03-27 2002-04-02 オレゴン ヘルス サイエンシーズ ユニバーシティー 腫瘍および他の過増殖性疾患の治療におけるビタミンｄおよびその類似体
US8263580B2 (en) * 1998-09-11 2012-09-11 Stiefel Research Australia Pty Ltd Vitamin formulation
US20090098065A1 (en) * 2000-01-11 2009-04-16 Avikam Harel Composition and methods for the treatment of skin disorders
WO2006120681A2 (en) * 2005-05-10 2006-11-16 Dermipsor Ltd. Compositions and methods for skin care
DE10010814A1 (de) * 2000-03-08 2001-09-13 Basf Ag Verwendung von 4-Oxoretinol und dessen Derivaten in kosmetischen Zubereitungen
JP2004504295A (ja) * 2000-07-18 2004-02-12 ボーン　ケア　インターナショナル　インコーポレイテッド 安定化１α−ヒドロキシビタミンＤ
US6566399B2 (en) * 2000-08-03 2003-05-20 Byung-Moo Min Inhibitor of replicative senescence of human keratinocytes containing retinoic acid as active ingredients
CN100391464C (zh) * 2001-12-03 2008-06-04 诺瓦西股份有限公司 含活性维生素d化合物的药物组合物
US20030143165A1 (en) * 2002-01-25 2003-07-31 Allan Evans NSAID-containing topical formulations that demonstrate chemopreventive activity
US7273607B2 (en) * 2002-07-01 2007-09-25 Karl G. Schakel, legal representative Health enhancement method
US20050026877A1 (en) * 2002-12-03 2005-02-03 Novacea, Inc. Pharmaceutical compositions comprising active vitamin D compounds
WO2004069134A2 (en) * 2003-02-05 2004-08-19 Galderma Research & Development, S.N.C. Invert emulsion type composition containing at least one active agent sensitive to the presence of water, and its uses in cosmetics and in dermatology
PT2476667E (pt) * 2003-02-26 2014-09-18 Sugen Inc Compostos de aminoheteroarilo como inibidores da proteína quinase
EP1628631A2 (en) * 2003-06-05 2006-03-01 Achkar, Charles C. Methods of treating hyperproliferative cell disorders
US20050020546A1 (en) * 2003-06-11 2005-01-27 Novacea, Inc. Pharmaceutical compositions comprising active vitamin D compounds
US20060189586A1 (en) * 2003-06-11 2006-08-24 Cleland Jeffrey L Pharmaceutical compositions comprising active vitamin D compounds
FR2862540B1 (fr) * 2003-11-21 2007-03-30 Galderma Res & Dev Composition sous forme de spray comprenant un actif pharmaceutique, au moins un silicone volatile et une phase non polaire non volatile
US8404667B2 (en) * 2006-12-29 2013-03-26 Wisconsin Alumni Research Foundation Compounds, compositions, kits and methods of use to orally and topically treat acne and other skin conditions by 19-Nor vitamin D analog
FR2871699A1 (fr) * 2004-06-17 2005-12-23 Galderma Sa Composition de type emulsion inverse contenant du calcitrol et du 17-propionate de clobetasol, et ses utilisations en cosmetiques et en dermatologie
US20060003950A1 (en) * 2004-06-30 2006-01-05 Bone Care International, Inc. Method of treating prostatic diseases using a combination of vitamin D analogues and other agents
US7094775B2 (en) * 2004-06-30 2006-08-22 Bone Care International, Llc Method of treating breast cancer using a combination of vitamin D analogues and other agents
US20060177390A1 (en) * 2005-02-08 2006-08-10 Person John R Skin cancer prevention method and product
US20100093674A1 (en) * 2005-08-04 2010-04-15 Person John R Skin cancer prevention method and product
US20060073107A1 (en) * 2004-10-04 2006-04-06 Person John R Use of vitamin D3 (cholecalciferol) in sunscreens
JP2008540514A (ja) * 2005-05-10 2008-11-20 ダーミプソル リミテッド 過剰増殖表皮疾患の治療用組成物及び方法
WO2006133828A1 (en) * 2005-06-17 2006-12-21 Dsm Ip Assets B.V. Novel use 25-hydroxycholecalciferol in combination with uv-b screening agents
FR2894465B1 (fr) * 2005-12-14 2010-09-10 Fabre Pierre Dermo Cosmetique Utilisation de composes polyinsatures en tant qu'agents blanchissants
US20080275128A1 (en) 2007-04-27 2008-11-06 Elliott C Lasser Compositions and methods for the treatment of inflammatory conditions
MX366076B (es) 2009-08-14 2019-06-27 Berg Llc Vitamina d3 y analogos de la misma para tratar alopecia.
US8747818B1 (en) * 2011-02-07 2014-06-10 Dennis Gross Self-tanning compositions
US11103520B2 (en) * 2014-04-23 2021-08-31 The Regents Of The University Of California Analogs of N-acetlyglucosamine and uses thereof
RU2016151314A (ru) * 2014-06-04 2018-07-09 АРБОНН ИНТЕРНЭШНЛ, ЭлЭлСи Прозрачные композиции и способы доставки активных ингредиентов для ухода за кожей
WO2016040638A2 (en) * 2014-09-10 2016-03-17 Washington University Compositions and methods for treatment of pre-cancerous skin lesions
US11752156B2 (en) 2018-03-07 2023-09-12 Athenex HK Innovative Limited Compositions and methods for treating hyperproliferative skin disorders

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5514672A (en) 1981-02-17 1996-05-07 Bazzano; Gail S. Use of retinoids and compositions containing same for hair growth
EP0133437A1 (en) * 1983-01-21 1985-02-27 Advanced Drug Technology Corporation Vitamin-containing skin care ointment
WO1987000834A1 (en) * 1985-08-02 1987-02-12 Leo Pharmaceutical Products Ltd. A/S Novel vitamin d analogues
JPS6360910A (ja) 1986-09-01 1988-03-17 Shiseido Co Ltd 皮膚外用剤
US5763428A (en) * 1990-09-21 1998-06-09 Bone Care International, Inc. Methods of treating skin disorders with novel 1a-hydroxy vitamin D4 compounds and derivatives thereof
GB9109733D0 (en) * 1991-05-07 1991-06-26 Unilever Plc Cosmetic composition
TW272187B (enExample) 1992-05-20 1996-03-11 Hoffmann La Roche
US5547947A (en) * 1993-03-11 1996-08-20 Hoffmann-La Roche Inc. Methods of treatment
FR2714595B1 (fr) 1993-12-30 1996-02-02 Oreal Emulsion eau dans huile contenant du rétinol, son utilisation et son conditionnement.
DE69529043T2 (de) 1994-09-30 2003-05-08 L'oreal S.A., Paris Verwendung von einem Agonisten eines mit einem Chloridkanal assozierten Rezeptors zur Behandlung von Hautfalten
US5786391A (en) 1995-01-11 1998-07-28 Cornell Research Foundation, Inc. Regulating gene expression using retinoids with Ch2 OH or related groups at the side chain terminal position
FR2738745B1 (fr) 1995-09-15 1997-10-24 Cird Galderma Nouvelles compositions a base d'un melange synergetique entre au moins un ligand de vdr et un retinoide, et leurs utilisations

Also Published As

Publication number Publication date
DK1104294T3 (da) 2006-02-13
DE69927507D1 (de) 2006-02-09
US20010002396A1 (en) 2001-05-31
JP2002527356A (ja) 2002-08-27
WO2000003700A1 (en) 2000-01-27
EP1104294A4 (en) 2003-02-05
MXPA01000492A (es) 2002-11-29
EP1104294B1 (en) 2005-09-28
EP1104294B8 (en) 2005-11-23
PT1104294E (pt) 2005-11-30
ES2249900T3 (es) 2006-04-01
ATE305296T1 (de) 2005-10-15
EP1104294A1 (en) 2001-06-06
CA2337138A1 (en) 2000-01-27
DE69927507T2 (de) 2006-03-23
US6242435B1 (en) 2001-06-05

Similar Documents

Publication Publication Date Title
EP1104294B8 (en) Compositions and methods of treating abnormal cell proliferation
HUP0100860A3 (en) Retinoic acid mimetic anilides, process for their preparation and pharmaceutical compositions containing them
UA66750C2 (en) Substituted 1-phenylpirazole 3-carboxamides, a method for the preparation thereof and intermediary compounds, pharmaceutical composition having affinity to neurotensin receptors
AU7291596A (en) Phenylacetic acid derivatives, processes and intermediates for their preparation, and compositions comprising them
MY141384A (en) Prevention of loss and restoration of bone mass by certain prostaglandin agonists
AU2003209259A1 (en) Novel mammalian multipotent stem cells and compositions, methods of preparation and methods of administration thereof
MXPA01006455A (es) Composiciones para el cuidado de la piel que contienen acido linoleico cis-9, trnas-11.
AU4643096A (en) Novel trienoic retinoid compounds and methods
WO1998058911A3 (en) Prostaglandin agonists
BG101892A (en) Sugar-modified cytostatics
HUP9802303A2 (hu) Kalcitriolszármazékok és gyógyászati alkalmazásuk
MY130044A (en) Retinoid composition
TW349000B (en) Fungicidal two-component composition based on R-metalaxyl and usage thereof
WO2002003912A3 (en) Novel c-4 substituted retinoids
AU2841199A (en) Novel bis-benzamide derivatives, method for making same pharmaceutical compositions containing them and use thereof as medicine
AU3252197A (en) Novel self-acid-doped highly conducting polythiophenes
WO2000030667A3 (en) Compositions and methods using lactadherin or variants thereof
AU2668800A (en) Mixture of plant-treatment agents and waxes, method for producing same and the use thereof
AU3076695A (en) Dinucleoside-5',5'-pyrophosphates
AU4745496A (en) Flavin adenine dinucleotide analogues, their pharmaceutical compositions, and their activity as monoamine oxidase inhibitors
AU2002348539A1 (en) ORAL IMMUNOSTIMULATION OF MAMMALS, BIRDS, AND REPTILES FROM (1-4) LINKED Beta-D-MANNURONIC ACID
MX9704948A (es) Retinoides triciclicos, metodos para su produccion y uso.
WO2001024803A3 (en) Pharmaceutical compositions containing copper, salicylic acid and vitamines c
AU4925200A (en) Oral composition containing perlite
TW371630B (en) Deodorizer

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase